A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation

Trial Profile

A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions; Registrational
  • Acronyms ULTRA-AF; VENTURE-AF
  • Sponsors Janssen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2015 According to a Janssen Pharmaceuticals media release, results of this trial build on the promising data observed in a sub analysis of the landmark ROCKET-AF trial (see profile 700020919).
    • 14 May 2015 According to a Janssen Pharmaceuticals media release, results from this trial were presented at the Heart Rhythm Society's 36th Annual Scientific Session and published in the European Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top